Oxford trial aims to prevent Lynch syndrome cancers with mRNA vaccine

A phase 1 trial by Oxford and Moderna is testing an mRNA vaccine (INTERCEPT – Lynch) designed to help the immune system identify and eliminate very early cancer changes in people with Lynch syndrome, potentially shifting care from treatment to prevention; the first participant, Sarah Ewart, marks a step toward validating safety and immune response with a plan to move to phase 2 across UK centres if successful.